SEC Filing | Astria Therapeutics

Names of reporting persons

Corriente Advisors, LLC

Check the appropriate box if a member of a group (see instructions)

(a) ☐ (b) ☐

SEC use only

Citizenship or place of organization

Delaware

View:

Download DOC

Download PDF

Download XLS

SC 13G/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13GA

Under the Securities Exchange Act of 1934

(Amendment No. 2)*

Catabasis Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, $0.001 par value per share

(Title of Class of Securities)

14875P206

(CUSIP Number)

December 31, 2019

(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☒ Rule 13d-1(c)

☐ Rule 13d-1(d)

*	The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13G

CUSIP No. 14875P206

(1)

Consists of (i) 617,084 outstanding shares of common stock of the Issuer, par value $0.001 per share (“Shares”), and (ii) 187,500 Shares issuable upon the exercise of warrants, in each case, directly held by Corriente Master Fund II, LP as of December 31, 2019. Corriente Advisors, LLC acts as an investment adviser to, and manages investment and trading accounts of, Corriente Master Fund II, LP. Corriente Advisors, LLC may be deemed to indirectly beneficially own securities held by Corriente Master Fund II, LP.

(2)

Based on 11,984,692 Shares, which consists of (i) 11,797,192 Shares outstanding as of October 31, 2019, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 7, 2019, and (ii) 187,500 Shares issuable upon the exercise of warrants held by Corriente Master Fund II, LP.


CUSIP No.		14875P206

(1)	Consists of (i) 617,084 outstanding shares of common stock of the Issuer, par value $0.001 per share (“Shares”), and (ii) 187,500 Shares issuable upon the exercise of warrants, in each case, directly held by Corriente Master Fund II, LP as of December 31, 2019.

(2)


CUSIP No.		14875P206

(1)

Consists of (i) 617,084 outstanding shares of common stock of the Issuer, par value $0.001 per share (“Shares”), and (ii) 187,500 Shares issuable upon the exercise of warrants, in each case, directly held by Corriente Master Fund II, LP as of December 31, 2019. Corriente Advisors, LLC acts as an investment adviser to, and manages investment and trading accounts of, Corriente Master Fund II, LP. Mr. Hart is the Chairman and Chief Executive Officer of Corriente Advisors, LLC. Mr. Hart may be deemed to indirectly beneficially own securities held by Corriente Master Fund II, LP.

(2)

Item 1(a)

Name of issuer:

Catabasis Pharmaceuticals, Inc.

Item 1(b)

Address of issuer’s principal executive offices:

One Kendall Square, Bldg. 1400E, Suite B14202, Cambridge, MA 02139

Item 2(a)

Name of person filing:

This Schedule is being filed on behalf of each of the following persons (each, a “Reporting Person” and collectively, the “Reporting Persons”)

Corriente Advisors, LLC (“Corriente Advisors”);

ii)

Corriente Master Fund II, LP (“Corriente Master Fund II”); and

iii)

Mark L. Hart III (“Mr. Hart”).

This Schedule relates to outstanding shares of common stock of the Issuer, par value $0.001 per share (“Shares”), as well as Shares issuable upon the exercise of warrants, in each case, directly held by Corriente Master Fund II as of December 31, 2019. Corriente Advisors acts as an investment adviser to, and manages investment and trading accounts of, Corriente Master Fund II. Corriente Advisors may be deemed to indirectly beneficially own securities held by Corriente Master Fund II. Mr. Hart is the Chairman and Chief Executive Officer of Corriente Advisors. Mr. Hart may be deemed to indirectly beneficially own securities held by Corriente Master Fund II.

Each Reporting Person declares that neither the filing of this Schedule nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, (i) acting (or has agreed or is agreeing to act) with any other person as a partnership, limited partnership, syndicate, or other group for the purpose of acquiring, holding, or disposing of securities of the Issuer or otherwise with respect to the Issuer or any securities of the Issuer or (ii) a member of any syndicate or group with respect to the Issuer or any securities of the Issuer.

Item 2(b)

Address or principal business office or, if none, residence:

The address of the principal business office of each of the Reporting Persons is 1401 Foch St, Suite 100, Fort Worth, TX 76107.

Item 2(c)

Citizenship:

Corriente Advisors is a Delaware limited liability company;

ii)

Corriente Master Fund II is a Cayman Islands limited partnership; and

iii)

Mr. Hart is a citizen of the United States of America.

Item 2(d)

Title of Class of Securities:

Common Stock, $0.001 par value per share

Item 2(e)

CUSIP No.:

14875P206

Item 3.

If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:


(a)		☐ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);

(b)		☐ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);

(c)		☐ Insurance company defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);

(d)		☐ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

(e)		☐ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f)		☐ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g)		☐ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h)		☐ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i)		☐ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);

(j)		☐ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);

(k)		☐ Group, in accordance with § 240.13d-1(b)(1)(ii)(K).

If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ______________.

Item 4.

Ownership

(a)

Amount Beneficially Owned:

As of December 31, 2019, each of the Reporting Persons may be deemed to be the beneficial owner of 804,584 Shares, which consists of (i) 617,084 outstanding Shares and (ii) 187,500 Shares issuable upon the exercise of warrants.

(b)

Percent of Class:

As of December 31, 2019, each of the Reporting Persons may be deemed to be the beneficial owner of approximately 6.71% of the Shares outstanding, based on 11,984,692 Shares, which consists of (i) 11,797,192 Shares outstanding as of October 31, 2019, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 7, 2019, and (ii) 187,500 Shares issuable upon the exercise of warrants held by Corriente Master Fund II.

(c)

Number of shares as to which such person has:

As of December 31, 2019, for each of the Reporting Persons:

(i)

Sole power to vote or to direct the vote: 0

(ii)

Shared power to vote or to direct the vote: 804,584

(iii)

Sole power to dispose or to direct the disposition of: 0

(iv)

Shared power to dispose or to direct the disposition of: 804,584

Item 5.

Ownership of Five Percent or Less of a Class.

Not applicable.

Item 6.

Ownership of More than Five Percent on Behalf of Another Person.

Not applicable.

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not applicable.

Item 8.

Identification and Classification of Members of the Group.

Not applicable.

Item 9.

Notice of Dissolution of Group.

Not applicable.

Item 10.

Certifications.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: January [__], 2020

CORRIENTE ADVISORS, LLC

/s/ Matthew Gilman

Chief Financial Officer

CORRIENTE MASTER FUND II, LP

/s/ Matthew Gilman

Chief Financial Officer of Corriente Advisors, LLC, the Investment Manager of Corriente Master Fund II, LP

MARK L. HART III

/s/ Mark L. Hart III

EXHIBIT INDEX


Exhibit		Page No.
A. Joint Filing Agreement		[__]

EX-99.A

EXHIBIT A

JOINT FILING AGREEMENT

The undersigned hereby agree that the statement on Schedule 13G with respect to the shares of common stock, par value $0.001 per share, of Catabasis Pharmaceuticals, Inc. dated as of January [__], 2020 is, and any amendments thereto signed by each of the undersigned shall be, filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.

CORRIENTE ADVISORS, LLC

/s/ Matthew Gilman

Chief Financial Officer

CORRIENTE MASTER FUND II, LP

/s/ Matthew Gilman

Chief Financial Officer of Corriente Advisors, LLC, the Investment Manager of Corriente Master Fund II, LP

MARK L. HART III

/s/ Mark L. Hart III